- Aptamers are short, single-stranded DNA or RNA molecules that bind to specific targets with high affinity and specificity, used in diagnostics, therapeutics, and research applications
- The demand for aptamers is significantly driven by increasing chronic disease prevalence, growing interest in targeted therapies, and advantages over antibodies such as lower immunogenicity and easier synthesis
- North America is expected to dominate the aptamers market with a market share of 45.5%, due to strong healthcare infrastructure, high adoption of advanced diagnostic and therapeutic technologies, and a robust presence of leading biotech companies
- Asia-Pacific is expected to be the fastest growing region in the aptamers market with a market share of 21.5%, during the forecast period due to rapid advancements in healthcare infrastructure, increasing awareness about personalized medicine, and rising investments in biotechnology research
- DNA-based aptamers segment is expected to dominate the market with a market share of 63.4% due to its higher stability, lower production costs, and ease of chemical modification compared to RNA-based and XNA-based aptamers
